

Attachment A

August 3, 2009

Amgen USA Inc. (Amgen) is making an adjustment to its PHS pricing for three Vectibix® (panitumumab) NDCs for the 2nd and 3rd quarters of 2008. PHS entities that purchased Vectibix® during those periods will receive a credit from their wholesaler within the next three months, as well as a letter about the change in price. Any questions should be directed to Pamela Sheng, Amgen Pricing & Contracts Specialist at (805) 447-2444. The NDCs at issue are listed below.

NDC	Description
55513-954-01	Vectibix® 100 mg, 5 mL (20 mg/mL) single-use vial
55513-955-01	Vectibix® 200 mg, 10 mL (20 mg/mL) single-use vial
55513-956-01	Vectibix® 400 mg, 20 mL (20 mg/mL) single-use vial